诺和锐30和诺和灵30R治疗2型糖尿病的临床比较

Clinical application of BIAsp 30 and BHI 30 in patients with type 2 diabetes

目的:研究诺和锐30和诺和灵30R治疗2型糖尿病的效果。方法:将84例2型糖尿病患者随机分为治疗组42例(诺和锐30)和对照组42例(诺和灵30R),均为每日2次皮下注射。应用12周,观察两组日胰岛素总量、血糖控制情况、体重及低血糖发生率。结果:两组的空腹血糖、餐后血糖、中餐前血糖及糖化血红蛋白较治疗前差异有统计学意义(P<0.05)。两组的空腹血糖、中餐前血糖及糖化血红蛋白下降值差异无统计学意义(P>0.05),而餐后血糖的下降值差异有统计学意义(P<0.05)。两组体重变化差异无统计学意义(P>0.05)。治疗组日胰岛素总量低于对照组,两组比较差异有统计学意义(P<0.05)。结论:治疗组的餐后血糖有明显降低,而且低血糖发生率较低,治疗2型糖尿病尤其以餐后血糖高为主的患者更适合使用。

Objective:To observe the curative effect of BIAsp30 and BHI30 in patients with type 2 diabetes.Methods:84 patients with type 2 diabetes using insulin were randomly divided into the treatment group(42 patients) and the control group(42 patients).The treatment group was treated with BIAsp30 and the control group was treated with BHI30 twice daily in morning and evening.Through 12 weeks'observation,the quantity of daily insulin,plasma glucose control,body weight and the incidence rate of low blood glucose were compared in two groups.Results:The blood glucose and HbA1c decreased distinctly in two groups after treatment(P<0.05).The FPG and HbA1c's descendent level of the two groups had no distinct difference(P>0.05).The PPG descendent level of treatment group had distinct difference(P<0.05).The body weight of the two groups had no distinct difference(P>0.05).The quantity of daily insulin in the two groups had distinct difference(P<0.05).Conclusion:The PPG of the treatment group distinctly descended.The incidence rate of low blood glucose in the treatment group was much lower than that in the control group.BIAsp30 is more suitable in patients with type 2 diabetes,especially in patients with high PPG.